

For on E l n e n d C e n d n d e o l E l n e o For on d e n o e o n o e
o n o n n o n e o , e n o e e o n o l l o o e e n d e e d l n
o e e o n o o o e e n o o n e n e o n e o e o n o e o n o o
n n o n e o .

FOSUN PHARMA 复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(o n o l d o n n o o d n e o e ' R e l o C n d)

(Stock Code: 02196)

2023 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the 2023 third quarterly report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “Company”, together with its subsidiaries, collectively the “Group”) (the “2023 Third Quarterly Report”) for the three months ended 30 September 2023 (the “Reporting Period”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and is unaudited.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

C n

Shanghai, the People's Republic of China

30th October 2023

A e d e o n n o n e o , e e e e d e l o o e C o n e . n , . n e n , .
G n o n d . o D e o n ; e n o n - e e e d e l o o e C o n e . C o l , . o F n , .
l l o n n d . n D o n ; n d e n d e o d o n o n - e e e d e l o o e C o n e . n , .
n G n , . n e n d n d . e n H o n .

* F o d o l o n o e o n

I. IMPORTANT NOTICE

The board of directors (the “**Board**”) and the supervisory committee (the “**Supervisory Committee**”) of the Company and its directors, supervisors and senior management warrant that the quarterly report does not contain any false information, misleading statements or material omission and severally and jointly accept legal responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

Mr. Wu Yifang, the person in charge of the Company, Ms. Yan Jia, the Chief Financial Officer, and Mr. Xie Lichun, the Director of the Accounting Department (Accounting Officer) warrant the truthfulness, accuracy and completeness of the financial information contained in the quarterly report of the Group.

The financial statements for the third quarter of 2023 of the Group are unaudited.

↓

	At the end of the Reporting Period			

(II) Extraordinary gain or loss items and amounts

Unit: Yuan Currency: RMB

Item	Amount of the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period
Gain or loss on disposal of non-current assets	607,167.23	240,042,762.32
Government grants included in profit or loss for the current period exclude government grants closely related to the Company's normal operation, and entitled in fixed amounts or quantities on a continuous basis according to national standards	12,936,211.49	63,918,044.58
Profit or loss arising from changes in the fair value of holding financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and investment income from disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except effective hedging business related to the Company's normal operations	622,275,288.80	1,196,809,546.90
Non-operating income and expenses other than those stated above	-22,600,495.18	-49,741,281.25
Other profit or loss items that fall within the meaning of extraordinary gain or loss	—	-61,283,586.24
Less: Effect of income tax	-197,071,787.31	-563,627,252.77
Impact on non-controlling interests (after tax)	-11,841,016.75	-16,966,750.49
Total	404,305,368.28	809,151,483.05

For extraordinary gain or loss items stated in the “Explanatory Announcement No. 1 on

(III) Changes in the principal accounting information and financial indicators and reasons for the changes

Name of item	Ratio of change (%)	Main reason
Net profit attributable to shareholders of the listed company for the Reporting Period	-43.85	Mainly due to (1) with the significant decline in the market demand on COVID-19 related products, COVID-19 related products and assets with the indication of impairment had been disposed by the Group. The Group also accrued provision for the impairment of related inventories, receivables and long-term assets during the Reporting Period. The combined effect of the aforementioned items was approximately RMB510 million; and (2) the period-on-period increase in administrative expenses and finance expenses.
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss for the Reporting Period	-89.84	Same as above
Basic earnings per share for the Reporting Period (RMB/share)	-44.12	Same as above
Diluted earnings per share for the Reporting Period (RMB/share)	-44.12	Same as above
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss for the first three quarters	-48.45	Apart from the aforementioned reasons for the decrease in “Net profit attributable to shareholders of the listed company for the Reporting Period”, the decrease was also due to (1) the significant decline in revenue from anti-epidemic products while the Group still incurred personnel, medical and marketing expenses; (2) the increase in finance expenses and exchange loss due to US\$ interest hikes, US\$ appreciation and other factors; and (3) the period-on-period increase in R&D expenses.
Net cash flow generated from operating activities for the Reporting Period	-51.55	Mainly due to the corresponding effect from changes in operating revenue and operating profit during the Reporting Period.

II. INFORMATION OF SHAREHOLDERS

(I) Total number of holders of ordinary shares and holders of preference shares with resumed voting rights, and the shareholding status of the Top 10 shareholders

Unit: Share

Total number of holders of ordinary shares as at the end of the Reporting Period	305,081	Total number of holders of preference shares with resumed voting rights as at the end of the Reporting Period (if any)	N/A			
The shareholding status of the Top 10 shareholders						
Name of shareholders	Capacity	Shareholding	Percentage of shareholding (%)	Number of restricted shares held	Shares pledged, marked or locked up	
					Status	Number
Fosun High Tech	Domestic non-state-owned legal entity	886,315,955 ^{o e 1}	33.16	0	Pledged	707,900,000
HKSCC NOMINEES LIMITED ^{o e 2}	Unknown	551,391,315	20.63	0	Unknown	—
China Securities Finance Corporation Limited* (中國證券金融股份有限公司)	Others	38,736,079	1.45	0	None	0
Hong Kong Securities Clearing Company Limited ^{o e 3}	Others	37,012,528	1.38	0	None	0
Bank of China Limited — China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (中國銀行股份有限公司—招商國證生物醫藥指數分級證券投資基金)	Securities investment fund	24,925,018	0.93	0	None	0
China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Trading Open-End Index Securities Investment Fund* (中國建設銀行股份有限公司—易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	Securities investment fund	18,960,946	0.71	0	None	0

The shareholding status of the Top 10 shareholders						
Name of shareholders	Capacity	Shareholding	Percentage of shareholding (%)	Number of restricted shares held	Shares pledged, marked or locked up	
					Status	Number
Industrial and Commercial Bank of China Limited — SSE Index 50 Trading Open-End Index Securities Investment Fund* (中國工商銀行股份有限公司—上證50交易型開放式指數證券投資基金)	Securities investment fund	12,135,208	0.45	0	None	0
Bank of Shanghai Co., Ltd. — Yinhua CSI Innovative Drug Industry Trading Open-End Index Securities Investment Fund* (上海銀行股份有限公司—銀華中證創新藥產業交易型開放式指數證券投資基金)	Securities investment fund	10,516,295	0.39	0	None	0
Industrial and Commercial Bank of China Limited — Huatai Borui CSI 300 Trading Open-end Index Securities Investment Fund* (中國工商銀行股份有限公司—華泰柏瑞滬深300交易型開放式指數證券投資基金)	Securities investment fund	8,157,025	0.31	0	None	0
Yunnan Qijia Investment Co., Ltd.* (雲南齊家投資有限公司)	Domestic non-state-owned legal entity	7,896,749	0.30	0	None	0

The shareholding status of the Top 10 unrestricted shareholders			
Name of shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type of shares	Number
Fosun High Tech	886,315,955 ^{o e 1}	RMB ordinary shares	886,315,955
HKSCC NOMINEES LIMITED ^{o e 2}	551,391,315	Overseas listed foreign shares	551,391,315
China Securities Finance Corporation Limited* (中國證券金融股份有限公司)	38,736,079	RMB ordinary shares	38,736,079
Hong Kong Securities Clearing Company Limited ^{o e 3}	37,012,528	RMB ordinary shares	37,012,528
Bank of China Limited — China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (中國銀行股份有限公司—招商國證生物醫藥指數分級證券投資基金)	24,925,018	RMB ordinary shares	24,925,018
China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Trading Open-End Index Securities Investment Fund* (中國建設銀行股份有限公司—易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	18,960,946	RMB ordinary shares	18,960,946
Industrial and Commercial Bank of China Limited — SSE Index 50 Trading Open-End Index Securities Investment Fund* (中國工商銀行股份有限公司—上證50交易型開放式指數證券投資基金)	12,135,208	RMB ordinary shares	12,135,208
Bank of Shanghai Co., Ltd. — Yinhua CSI Innovative Drug Industry Trading Open-End Index Securities Investment Fund* (上海銀行股份有限公司—銀華中證創新藥產業交易型開放式指數證券投資基金)	10,516,295	RMB ordinary shares	10,516,295
Industrial and Commercial Bank of China Limited — Huatai Borui CSI 300 Trading Open-end Index Securities Investment Fund* (中國工商銀行股份有限公司—華泰柏瑞滬深300交易型開放式指數證券投資基金)	8,157,025	RMB ordinary shares	8,157,025
Yunnan Qijia Investment Co., Ltd.* (雲南齊家投資有限公司)	7,896,749	RMB ordinary shares	7,896,749
Description of the related relationship or concerted action of the above shareholders	At as the end of the Reporting Period, except for holding 886,315,955 A shares of the Company by itself, Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司) (“Fosun High Tech”), the controlling shareholder, and its controlling shareholder, Fosun International Limited (“Fosun International”), held 71,533,500 and 6,000,000 H shares of the Company through HKSCC NOMINEES LIMITED, respectively. Save as disclosed above, the Company does not know whether any related relationship or concerted action exists between any of other abovementioned shareholders of tradable shares.		
Status description of Top 10 shareholders and Top 10 unrestricted shareholders participating in securities margin trading and refinancing business (if any)	Yunnan Qijia Investment Co., Ltd.* (雲南齊家投資有限公司) holds 7,896,749 shares, all of which are held through securities margin trading account.		

^{o e 1}: Representing A shares only. At as the end of the Reporting Period, Fosun High Tech, the controlling shareholder, held an aggregate of 957,849,455 shares of the Company (including 886,315,955 A shares and 71,533,500 H shares), representing approximately 35.84% of the total shares of the Company as at the end of the Reporting Period.

- Note 2: HKSCC NOMINEES LIMITED, i.e. Hong Kong Securities Clearing Company Nominees Limited, is holding shares on behalf of multiple clients (shares held by it at the end of the Reporting Period includes an aggregate of 77,533,500 H shares of the Company held by Fosun High Tech, the Company's controlling shareholder, and its controlling shareholder, Fosun International, through it, representing approximately 2.90% of the total share capital of the Company as at the end of the Reporting Period).
- Note 3: Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB ordinary shares under Shanghai-Hong Kong Stock Connect.

III. OTHER REMINDER

The investors are reminded to pay attention to other significant information concerning the Company's operations during the Reporting Period

(I) Overview of operating results

In the first three quarters of 2023, upholding the "4IN" strategy, the Group persisted in the development pattern of "innovation and transformation, integrated operation and steady development" and the mission of creating value for the shareholders, and continued to enhance self-R&D capacity and external cooperation, enrich its product pipelines, and strengthen its international layout.

In 2023, under the backdrop of deepening the reform in pharmaceutical industry, the Group continued to promote innovative R&D driven by clinical demands, and accelerated product transformation. Meanwhile, with the sharp decline in market demand on COVID-19 related products, the Group conducted the disposal on relevant products and reassessed relevant assets during the Reporting Period. In the first three quarters of 2023, the operating revenue of the Group amounted to RMB30.700 billion, net profit attributable to shareholders of the listed company amounted to RMB2.283 billion (in particular, net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss amounted to RMB1.474 billion), net cash flow generated from operating activities amounted to RMB2.462 billion. In the first three quarters of 2023, excluding anti-epidemic products, the operating revenue of the Group recorded a period-on-period increase of approximately 11%; excluding anti-epidemic products, the revenue from new products and sub-new products of the pharmaceutical manufacturing segment recorded a period-on-period increase of over 30%.

In the first three quarters of 2023, the Group continued to increase R&D expenditure. The total R&D expenditure amounted to RMB4.291 billion, representing a period-on-period increase of 13.67%. In particular, the R&D expenses amounted to RMB3.155 billion, representing a period-on-period increase of RMB292 million or 10.22%.

Since July 2023, the Group's main operations and product R&D progress are as follows:

1. *Clinical development pipeline*

- (i) An innovative product/indication has been approved for launch: During the Reporting Period, Han Si Zhuang (serplulimab injection), the first self-developed biopharmaceutical innovative drug of the Group, had been approved for new indication for esophageal squamous cell carcinoma (ESCC). As at the end of the Reporting Period, Han Si Zhuang (serplulimab injection) had been approved for four indications, namely (1) microsatellite instability-high (MSI-H) solid tumors, (2) squamous non-small cell lung cancer (NSCLC), (3) extensive-stage small cell lung cancer (ES-SCLC), and (4) esophageal squamous cell carcinoma (ESCC).
- (ii) A number of products independently developed and licensed-in have successively entered the critical clinical/approval stage: During the Reporting Period, independently developed by the Group, the first patient dosing in the phase III of the international multi-center clinical study of Han Si Zhuang (serplulimab injection) in combination with chemotherapy and concurrent radiotherapy for the treatment of limited-stage small cell lung cancer (LS-SCLC) was completed in the European Union; the phase III clinical research of FCN-159 for the treatment of neurofibromatosis type I in adults commenced in Chinese mainland (excluding Hong Kong, Macau and Taiwan, China, the same below), and its another indication, namely treatment for adult patients with NF1 (neurofibromatosis type I) related plexiform neurofibroma who are unable to undergo surgery or encounter postoperative residual/recurrence, was included in the breakthrough therapy drug program; the phase II clinical research of FCN-338 in combination with azacitidine or chemotherapy for the treatment of myeloid malignancies commenced in Chinese mainland; the phase III clinical research of ET-26 (methoxyetomidate hydrochloride for injection) for the induction of general anesthesia in adults commenced in Chinese mainland in October 2023. In addition, during the Reporting Period, both the new drug applications of DaxibotulinumtoxinA botulinum toxin (project code: RT002) for the medical indication (treatment for cervical dystonia in adults), and tenapanor hydrochloride tablets (project code: Tenapanor) proposed for controlling hyperphosphatemia in adult patients receiving hemodialysis treatment for chronic kidney disease (CKD), being license-in drugs of the Group, were accepted by the National Medical Products Administration of the People's Republic of China.

2. *Acquisition of Medical Device Manufacturing License*

In August 2023, Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd.* (直觀復星醫療器械技術(上海)有限公司), an associated company, obtained the Medical Device Manufacturing License (《醫療器械生產許可證》) for its domestically-manufactured surgical robot. In October 2023, its first domestically-manufactured Da Vinci Xi Surgical System (i.e. “thoracic and abdominal endoscopy surgical control system”) officially debuted, marking the domestic manufacturing of the world’s leading Da Vinci Surgical Robot. As the fourth generation of Da Vinci Surgical System, the system can be applied in endoscopic surgeries in urology, general surgery, obstetrics and gynecology, thoracic surgery, etc. The domestic manufacturing of Da Vinci Surgical System will further enhance the accessibility of such series of product and benefit more patients in China.

3. *Expansion of International Cooperation*

During the Reporting Period, Shanghai Henlius Biotech, Inc.* (上海復宏漢霖生物技術股份有限公司) (“**Shanghai Henlius**”), a subsidiary, and PT Kalbe Genexine Biologics reached an agreement in relation to serplulimab injection (PD-1 inhibitor), enabling their scope of cooperation to further expand to cover 12 countries in the Middle East and North Africa from the original 10 countries in Southeast Asia. In addition, in October 2023, Shanghai Henlius and Intas Pharmaceuticals Ltd. (“**Intas**”) also reached a license agreement, pursuant to which Shanghai Henlius granted Intas the exclusive commercialization rights and other rights of serplulimab injection (PD-1 inhibitor) in the agreed Europe and India to enhance the accessibility and recognition of such product in the international market.

(II) Others

1. *Share Acquisition*

Fosun High Tech, a controlling shareholder, by itself (and/or parties acting in concert with it), proposed to further increase its shareholding in the Company (including A shares and/or H shares) by way of, including but not limited to, centralized price bidding or block trade at the stock exchanges and transfer by agreement within the 12-month period commencing from 13 September 2023 (inclusive), if and where appropriate, and the cumulative total consideration thereof shall not be less than RMB100 million or equivalent (with the total amount for the shareholding increase in A shares no less than RMB100 million) and the additional shareholding interest to be acquired by the aforesaid party(ies) in aggregate shall not exceed 2% of the total issued shares of the Company as at 13 September 2023 (i.e. 2,672,156,611 shares, the same applies below) (and the aggregated number of shares of the Company to be acquired in the 12-month period on a rolling basis shall not exceed 2% of the total issued shares of the Company). The

shareholding increase party/parties will not reduce its/their shareholding in the Company during the implementation of the shareholding increase plan and within the statutory restricted period.

As at the end of the Reporting Period, Fosun High Tech increased its shareholding of a total of 720,000 shares of the Company (all of which were A shares) under the shareholding increase plan, representing approximately 0.03% of the total issued shares of the Company as at 13 September 2023, with a total purchase price of approximately RMB20.0822 million.

2. *Adjustment of investment projects*

In order to speed up the progress of R&D of innovative drugs and improve the efficiency of the use of proceeds, taking into account the progress of the innovative R&D projects of the Group, the proposal on the adjustment to the investment amounts for certain investment projects of the 2022 non-public issuance of A shares and addition of new investment sub-projects was considered and approved at each of the 31st meeting of the ninth session of the Board and the 4th meeting in 2023 of the ninth session of the Supervisory Committee, the details of which include (1) apply the proceeds originally planned for use in the “intensive comprehensive base for active pharmaceutical ingredients and preparations” project amounting to RMB193.14 million (being the portion that has not been invested) to another investment project, i.e. the “innovative drug clinical, license-in and relevant marketing preparation” project, and (2) optimize the investment allocation among the sub-projects under the “innovative drug clinical, license-in and relevant marketing preparation” project and add sub-projects thereunder. The adjustment had been approved at the 2023 first extraordinary general meeting of the Company convened on 13 October 2023.

IV. APPENDICES

(I) Audited report

Not applicable



Consolidated Balance Sheet (Continued)

30 September 2023

Items	30 September 2023	31 December 2022
Current liabilities:		
Short-term loans	15,433,493,833.15	11,931,537,165.93
Bills payable	665,284,406.18	857,879,140.38
Trade payable	5,594,485,550.43	5,426,161,923.19
Contract liabilities	1,264,365,084.06	1,544,762,576.49
Wages payable	1,628,196,707.34	1,640,222,238.38
Tax payable	765,717,365.27	929,835,697.13
Other payables	4,142,967,669.55	5,353,265,590.30
Including: Interests payable	—	—
Dividends payable	21,111,041.46	34,443,965.75
Non-current liabilities due within one year	4,905,257,302.75	5,471,331,900.27
Other current liabilities	106,529,733.71	143,073,225.18
Total current liabilities	34,506,297,652.44	33,298,069,457.25
Non-current liabilities:		
Long-term loans	12,225,867,713.10	11,600,437,131.66
Bonds payable	—	499,431,152.21
Lease liabilities	814,838,276.82	744,992,648.18
Long-term payables	450,728,393.92	337,819,540.68
Long-term wages payable	30,715,060.80	42,068,155.09
Deferred income	606,844,348.48	632,432,895.82
Deferred tax liabilities	3,494,082,300.04	3,362,940,237.33
Other non-current liabilities	2,655,510,796.56	2,536,806,400.77
Total non-current liabilities	20,278,586,889.72	19,756,928,161.74
Total liabilities	54,784,884,542.16	53,054,997,618.99
Owners' Equity (or shareholders' equity):		
Share capital	2,672,528,211.00	2,672,156,611.00
Capital reserve	16,955,730,215.89	16,992,138,223.00
Less: Treasury shares	61,166,170.00	53,254,806.00
Other comprehensive income	-1,012,301,118.40	-1,198,363,947.81
Surplus reserve	2,952,929,442.20	2,952,929,442.20
Unappropriated profit	24,411,655,688.44	23,216,851,990.16
Total equity attributable to the owners (or shareholders) of the parent company	45,919,376,269.13	44,582,457,512.55
Non-controlling interests	10,062,983,485.52	9,526,452,100.80
Total owners' equity (or shareholders' equity)	55,982,359,754.65	54,108,909,613.35
Total liabilities and owners' equity (or shareholders' equity)	110,767,244,296.81	107,163,907,232.34

中国银行股份有限公司
 行长：
Wu Yifang

首席执行官：
Yan Jia

董事长：
Xie Lichun

Consolidated Income Statement

— e e e 2023

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2023 (Jan–Sept)	First three quarters of 2022 (Jan–Sept) (Restated)
I. Total operating revenue	30,700,119,056.12	31,622,769,575.50
Including: Operating revenue	30,700,119,056.12	31,622,769,575.50
II. Total operating costs	30,284,279,170.47	29,443,430,126.13
Including: Operating costs	15,779,521,220.28	16,912,488,475.00
Tax and surcharges	197,962,111.28	164,784,977.07
Selling expenses	7,226,681,929.85	6,497,034,824.72
General and administrative expenses	3,168,933,375.04	2,627,406,775.01
Research and development expenses	3,155,101,729.15	2,862,643,999.21
Finance expenses	756,078,804.87	379,071,075.12
Including: Interest expenses	947,670,221.32	698,728,193.33
Interest income	265,614,789.02	198,224,473.75
Plus: Other gains	303,789,784.16	247,149,830.82
Investment income (“–” indicating loss)	2,182,417,314.63	3,053,470,757.55
Including: Investment income from associates and joint ventures	1,495,922,362.55	1,220,658,910.22
Gains from changes in fair value (“–” indicating loss)	806,336,386.57	–1,930,779,093.73
Credit impairment losses (“–” indicating loss)	–81,582,526.65	–34,904,497.28
Asset impairment losses (“–” indicating loss)	–290,902,742.88	–93,589,712.36
Gains from disposal of assets (“–” indicating loss)	6,299,669.38	140,104,537.54
III. Operating profit (“–” indicating loss)	3,342,197,770.86	3,560,791,271.91
Plus: Non-operating revenue	49,590,722.66	16,763,170.34
Less: Non-operating expenses	99,332,003.91	206,476,966.56
IV. Total profit (“–” indicating total loss)	3,292,456,489.61	3,371,077,475.69
Less: Income tax expenses	638,646,952.94	611,539,705.21
V. Net profit (“–” indicating net loss)	2,653,809,536.67	2,759,537,770.48
(I) Classification according to the continuity of operation		
1. Net profit from continuing operation (“–” indicating net loss)	2,653,809,536.67	2,759,537,770.48
2. Net profit from discontinued operation (“–” indicating net loss)	—	—
(II) Classification according to ownership		
1. Net profit attributable to the owners of the parent company (“–” indicating net loss)	2,283,065,930.63	2,436,199,195.90
2. Profit or loss attributable to non-controlling interests (“–” indicating net loss)	370,743,606.04	323,338,574.58

Consolidated Income Statement (Continued)

— 2023

Items	First three quarters of 2023 (Jan–Sept)	First three quarters of 2022 (Jan–Sept) (Restated)
VI. Other comprehensive income, net of tax	383,047,217.57	450,398,730.53
(I) Other comprehensive income attributable to the owners of the parent company, net of tax	219,204,955.15	275,772,725.20
1. Other comprehensive income not reclassified subsequently to profit or loss	-50,170.88	-10,194,957.34
(1) Change in re-measurement of defined benefit plan	—	—
(2) Other comprehensive income using the equity method that will not be reclassified to profit or loss	—	—
(3) Change in the fair value of other equity instrument investments	-50,170.88	-10,194,957.34
(4) Change in the fair value of credit risk of the company	—	—
2. Other comprehensive income reclassified subsequently to profit or loss	219,255,126.03	285,967,682.54
(1) Other comprehensive income using the equity method that will be reclassified to profit or loss	-74,114,634.97	-80,381,297.42
(2) Changes in fair value of other equity instrument investments	—	—
(3) Financial assets reclassified to other comprehensive income	—	—
(4) Credit impairment provision for other equity investments	—	—
(5) Cash flow hedge reserve	—	—
(6) Exchange differences on translation of foreign currency financial statements	293,369,761.00	366,348,979.96
(7) Others	—	—
(II) Other comprehensive income attributable to non-controlling interests, net of tax	163,842,262.42	174,626,005.33
VII. Total comprehensive income	3,036,856,754.24	3,209,936,501.01
(I) Total comprehensive income attributable to the owners of the parent company	2,502,270,885.78	2,711,971,921.10
(II) Total comprehensive income attributable to non-controlling interests	534,585,868.46	497,964,579.91
VIII. Earnings per share:		
(I) Basic earnings per share (yuan/share)	0.86	0.94
(II) Diluted earnings per share (yuan/share)	0.85	0.94

e O n n a e o
e G n :
Wu Yifang

C e F n n a e :
Yan Jia

D e o o
e A o n n D e a :
Xie Lichun

Consolidated Statement of Cash Flow

— e e e 2023

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2023 (Jan–Sept)	First three quarters of 2022 (Jan–Sept) (Restated)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	31,291,201,615.51	31,895,192,604.72
Refund of taxes and levies	282,616,022.96	569,341,059.63
Cash received relating to other operating activities	1,862,007,814.60	1,270,507,388.02
Sub-total of cash inflow generated from operating activities	33,435,825,453.07	33,735,041,052.37
Cash paid for purchasing goods and receiving services	12,960,139,678.42	15,840,417,639.08
Cash paid to and on behalf of employees	8,032,804,716.41	6,879,566,228.31
Cash paid for all types of taxes	2,066,345,801.66	1,816,143,647.43
Cash paid relating to other operating activities	7,914,894,769.94	6,055,180,856.63
Sub-total of cash outflow generated from operating activities	30,974,184,966.43	30,591,308,371.45
Net cash flow generated from operating activities	2,461,640,486.64	3,143,732,680.92
II. Cash flow generated from investing activities:		
Cash received from disposal of investments	971,683,442.14	1,999,539,052.44
Cash received from returns on investments	888,386,091.11	781,242,948.26
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	7,183,164.91	139,770,144.72
Net cash received from disposal of subsidiaries and other operating segments	—	704,493,200.43
Cash received relating to other investing activities	1,260,013,178.06	282,767,712.51
Sub-total of cash inflow generated from investing activities	3,127,265,876.22	3,907,813,058.36
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	4,217,498,536.44	4,476,102,379.14
Cash paid for investments	691,319,201.85	862,199,305.24
Net cash paid for acquisition of subsidiaries and other operating segments	1,145,321,504.56	1,185,925,636.44
Cash paid relating to other investing activities	357,419,663.99	1,586,146,225.74
Sub-total of cash outflow generated from investing activities	6,411,558,906.84	8,110,373,546.56
Net cash flow generated from investing activities	-3,284,293,030.62	-4,202,560,488.20

Consolidated Statement of Cash Flow (Continued)

— 2023

Items	First three quarters of 2023 (Jan–Sept)	First three quarters of 2022 (Jan–Sept) (Restated)
III. Cash flow generated from financing activities:		
Cash received from capital contribution	43,943,339.47	4,576,106,656.28
Including: Cash received by subsidiaries from investments of non-controlling interests	43,943,339.47	119,907,907.76
Cash received from borrowings	18,051,361,530.05	24,765,091,427.40
Cash received relating to other financing activities	341,238,916.65	543,599,653.56
Sub-total of cash inflow generated from financing activities	18,436,543,786.17	29,884,797,737.24
Cash paid for debts settlement	15,547,919,509.95	20,782,333,623.69
Cash paid for the distribution of dividends, profits or interests	2,281,793,707.17	2,250,716,593.12
Including: Dividends and profits paid by subsidiaries to non-controlling interests	188,537,457.63	137,446,317.40
Cash paid relating to other financing activities	1,003,410,173.53	1,878,679,627.59
Sub-total of cash outflow generated from financing activities	18,833,123,390.65	24,911,729,844.40
Net cash flow generated from financing activities	-396,579,604.48	4,973,067,892.84
IV. Effects of exchange rate fluctuations on cash and cash equivalents	131,327,968.77	319,317,772.15
V. Net increase of cash and cash equivalents	-1,087,904,179.69	4,233,557,857.71
Plus: Opening balance of cash and cash equivalents	11,170,066,988.55	6,459,717,065.10
VI. Closing balance of cash and cash equivalents	10,082,162,808.86	10,693,274,922.81

财务总监
 财务总监：
Wu Yifang

财务总监
 财务总监：
Yan Jia

财务总监
 财务总监：
Xie Lichun

Balance Sheet of the Parent Company

30 e e e 2023

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2023	31 December 2022
Current assets:		
Cash and bank balances	1,880,211,237.82	2,283,272,306.06
Financial assets held for trading	131,235,142.10	—
Other receivables	3,869,327,410.52	5,815,866,192.54
Including: Interests receivable	—	—
Dividends receivable	1,014,750,826.36	1,182,342,267.01
Assets held for sale	419,577,812.78	419,577,812.77
Non-current assets due within one year	2,786,442,593.75	2,911,442,593.75
Other current assets	794,710,955.42	737,149,385.36
Total current assets	9,881,505,152.39	12,167,308,290.48
Non-current assets:		
Long-term equity investments	33,422,188,692.51	32,380,044,093.87
Other non-current financial assets	39,099,193.39	312,796,468.29
Fixed assets	7,372,487.99	6,477,908.86
Intangible assets	1,393,842.39	1,607,738.50
Other non-current assets	4,674,599,915.70	4,667,335,090.56
Total non-current assets	38,144,654,131.98	37,368,261,300.08
Total assets	48,026,159,284.37	49,535,569,590.56
Current liabilities:		
Short-term loans	4,577,825,026.53	3,146,359,896.23
Wages payable	112,906,033.52	117,872,193.95
Tax payable	29,904,950.94	27,006,397.41
Other payables	3,177,741,645.99	3,505,435,367.91
Non-current liabilities due within one year	3,108,323,355.13	3,643,339,110.32
Other current liabilities	164,352,820.54	209,162,359.43
Total current liabilities	11,171,053,832.65	10,649,175,325.25
Non-current liabilities:		
Long-term loans	1,618,855,947.50	2,997,800,000.00
Bonds payable	—	499,431,152.21
Long-term wages payable	25,279,060.77	2,576,545.14
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79
Total non-current liabilities	2,795,153,882.06	4,650,826,571.14
Total liabilities	13,966,207,714.71	15,300,001,896.39

Balance Sheet of the Parent Company (Continued)

30 September 2023

Items	30 September 2023	31 December 2022
Owners' Equity (or shareholders' equity):		
Share capital	2,672,528,211.00	2,672,156,611.00
Capital reserve	18,760,369,461.51	18,750,823,068.12
Less: Treasury shares	61,166,170.00	53,254,806.00
Other comprehensive income	-255,994,345.00	-157,364,697.37
Surplus reserve	1,336,078,305.50	1,336,078,305.50
Unappropriated profit	11,608,136,106.65	11,687,129,212.92
Total owners' equity (or shareholders' equity)	34,059,951,569.66	34,235,567,694.17
Total liabilities and owners' equity (or shareholders' equity)	48,026,159,284.37	49,535,569,590.56

e o n n a e o

e Co n :

Wu Yifang

C e F n n a e :

Yan Jia

D e o o

e A o n n D e a :

Xie Lichun

Income Statement of the Parent Company (Continued)

— 2023

Items	First three quarters of 2023 (Jan–Sept)	First three quarters of 2022 (Jan–Sept)
V. Other comprehensive income, net of tax	-65,487,521.89	-80,245,756.42
(I) Other comprehensive income not reclassified subsequently to profit or loss	—	—
1. Change in re-measurement of defined benefit plan	—	—
2. Other comprehensive income using the equity method that will not be reclassified to profit or loss	—	—
3. Changes in fair value of other equity instrument investments	—	—
4. Change in the fair value of credit risk of the company	—	—
(II) Other comprehensive income reclassified subsequently to profit or loss	-65,487,521.89	-80,245,756.42
1. Other comprehensive income using the equity method that will be reclassified to profit or loss	-65,487,521.89	-80,245,756.42
2. Change in the fair value of other equity instrument investments	—	—
3. Financial assets reclassified to other comprehensive income	—	—
4. Credit impairment provision for other equity investments	—	—
5. Cash flow hedge reserve	—	—
6. Exchange differences on translation of foreign currency financial statements	—	—
7. Others	—	—
VI. Total comprehensive income	943,781,604.19	1,214,865,431.51
VII. Earnings per share:		
(I) Basic earnings per share (yuan/share)	N/A	N/A
(II) Diluted earnings per share (yuan/share)	N/A	N/A

董事长

Wu Yifang

财务总监

Yan Jia

董事

Xie Lichun

(III) Status in relation to adjustments to the first implementation of financial statements at the beginning of the year for the implementation of new accounting standards for the first time from 2023

Not applicable

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
C 汪

Shanghai, the People's Republic of China
30 October 2023

* 上海医药集团股份有限公司